Jindarui: Plans to increase capital by 30 million yuan, acquiring a 10% stake in Zhongke Hongtai.

Jindalai announced that the company plans to increase its capital by 30 million yuan to Beijing Zhongke Hongtai Medical Technology Co., Ltd. with its own funds, and will hold 10% equity after the completion of the transaction. This investment has been approved by the company's internal review and does not constitute a major asset restructuring or related party transaction. Zhongke Hongtai was founded by Professor Hou Zengguang's team and has strong research capabilities in the field of medical artificial intelligence. Its products have entered the special review process for innovative medical devices by the National Medical Products Administration. However, the company is currently not profitable, with revenue of 102,600 yuan and a net loss of 5.5077 million yuan from January to September 2025. There is uncertainty in future operating performance and investment returns.